Related Experiment Videos

Neonatal Guillain-Barré syndrome: blocking antibodies transmitted from mother to child

B Buchwald1, M de Baets, G J Luijckx

  • 1Neurologische Klinik der Bayerischen, Julius-Maximilians-Universität, Würzburg, Germany.

Neurology
|October 16, 1999
PubMed

Insights

Blocking antibodies transferred from mother to infant caused neonatal Guillain-Barré syndrome (GBS). These antibodies targeted mature neuromuscular junctions, explaining the delayed onset of GBS in the neonate.

Area of Science:

  • Neurology
  • Immunology
  • Developmental Biology

Background:

  • Neonatal Guillain-Barré syndrome (GBS) is rare but severe.
  • Maternal GBS can pose risks to the neonate via transplacental antibody transfer.

Observation:

  • A neonate born to a mother with active GBS developed the condition 12 days postpartum.
  • Maternal and infant serum samples showed significant blockade of neuromuscular transmission.

Findings:

  • Blocking antibodies, confirmed by immunoglobulin G (IgG) and Fab fragments, reduced quantal content by 90% and postsynaptic current amplitude by 30-40%.
  • IgM antibodies to GM1 ganglioside were detected, but not IgG to common GBS targets.
  • Blocking activity was absent in recovered mother and infant sera and in 5-day-old rats, but present in 23-day-old rats.

Implications:

  • Transplacentally transferred blocking antibodies may target mature, but not fetal, neuromuscular junction epitopes.
  • This antibody specificity could explain the delayed onset of neonatal GBS.
  • Understanding these mechanisms is crucial for managing maternal and neonatal autoimmune neurological disorders.
Abstract

Related Concept Videos